Corticotropin

Generic Name: Corticotropin

Brand Names: Acthar, Cortrophin

Drug Type: Biotech

Chemical Formula: -

CAS Number: 12427-33-7

Unique Ingredient Identifier: K0U68Q2TXA

Background: Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication: For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions: Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis

Associated Therapies: -

Clinical Trials

Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis

Early Phase 1

Completed

Conditions: Optic Neuritis

Interventions: Drug: ACTHAR

First Posted Date: 2013-11-19

Last Posted Date: 2017-08-22

Lead Sponsor: Neuro-Ophthalmologic Associates, PC

Target Recruit Count: 25

Registration Number: NCT01987167

Locations: 🇺🇸
Neuro Ophthalmology, Philadelphia, Pennsylvania, United States

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: ACTHAR

First Posted Date: 2013-11-14

Last Posted Date: 2021-01-15

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 15

Registration Number: NCT01984268

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

ACTH in Progressive Forms of MS

Phase 2

Terminated

Conditions: Primary Progressive Multiple Sclerosis
Progressive Relapsing Multiple Sclerosis
Secondary Progressive Multiple Sclerosis

Interventions: Drug: Placebo
Drug: ACTH

First Posted Date: 2013-09-25

Last Posted Date: 2023-05-16

Lead Sponsor: University of Minnesota

Target Recruit Count: 59

Registration Number: NCT01950234

Locations: 🇺🇸
Sanford Clinic Neuroscience, Fargo, North Dakota, United States
🇺🇸
Clinical Neuroscience Research Unit, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Wheaton Franciscan Healthcare - St Francis Center for Neurological Disorders, Milwaukee, Wisconsin, United States

A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines

Phase 2

Completed

Conditions: Chronic Migraine

Interventions: Drug: H.P. Acthar Gel

First Posted Date: 2013-03-19

Last Posted Date: 2018-07-26

Lead Sponsor: Dent Neuroscience Research Center

Target Recruit Count: 20

Registration Number: NCT01813591

Locations: 🇺🇸
Renown Institute of Neurosciences, Reno, Nevada, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
Dent Neurologic Institute, Amherst, New York, United States

and more 1 locations

Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

Phase 4

Completed

Conditions: Lupus Erythematosus Systemic Exacerbation

Interventions: Drug: H.P. Acthar Gel

First Posted Date: 2013-01-17

Last Posted Date: 2013-07-23

Lead Sponsor: Fiechtner, Justus J., M.D., P.C.

Target Recruit Count: 10

Registration Number: NCT01769937

Locations: 🇺🇸
Justus J. Fiechtner, Lansing, Michigan, United States

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

Phase 4

Completed

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: Acthar
Drug: Steroid Drug
Drug: Placebo

First Posted Date: 2012-12-20

Last Posted Date: 2020-02-27

Lead Sponsor: Mallinckrodt

Target Recruit Count: 38

Registration Number: NCT01753401

Locations: 🇺🇸
Mallinckrodt Investigational Site, Houston, Texas, United States

Dermatomyositis and Polymyositis Registry

Conditions: Dermatomyositis
Polymyositis

First Posted Date: 2012-07-10

Last Posted Date: 2015-11-06

Lead Sponsor: Phoenix Neurological Associates, LTD

Target Recruit Count: 100

Registration Number: NCT01637064

Locations: 🇺🇸
PNA Center for Neurological Research, Phoenix, Arizona, United States
🇺🇸
Neurology INC, Columbia, Missouri, United States
🇺🇸
New York Methodist Hospital, Brooklyn, New York, United States

and more 2 locations